Note This Is A Wednesday Luncheon Meeting

Breakthrough?

New Treatment Approaches in Alzheimer’s Disease

Currently available Alzheimer’s treatments are of limited benefit. With the number of cases worldwide expected to triple in the next 30 years, there is an urgent need to find treatments that treat the cause of the disease, rather than just mask the symptoms. Steve Macfarlane has been running Alzheimer’s trials for almost 20 years, including a Melbourne-based study of a new drug, Anavex 2-73, in which patients have shown signs of significant benefit

‘When Melbourne was selected as the first city in the world to test Anavex a year ago, lead researcher Associate Professor Steve Macfarlane had no idea how much of an impact it would make.

‘……seem to be significantly improved in terms of what they can do. It is function that has improved and in many cases mood as well,” Prof Macfarlane said.

‘To me, seeing real improvements to patients is much more important than seeing a statistically significant improvement on a rating scale’. (news.com.au)

Chair:  David Rosback